Meyka Pro banner
Nuvalent, Inc.

Nuvalent, Inc. (NUVL) Stock Overview

Explore Nuvalent, Inc.’s financial performance, market position, analyst ratings, and future outlook.

NUVLNASDAQ
HealthcareBiotechnology
$123.96
$0.00(0.00%)
U.S. Market opens in 62h 16m

Nuvalent, Inc. (NUVL)

Meyka AI Score

Z

Key Financials

Market Cap9.1B
P/E Ratio-20.46
EPS (TTM)$-5.69
ROE-0.43%
Fundamental Analysis

AI Price Forecasts

1 Month$114.08
3 Months$144.52
1 Year Target$123.90

NUVL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Nuvalent, Inc. (NASDAQ: NUVL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Nuvalent, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of NUVL on the NASDAQ shows an RSI of 70.82, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $123.90 for the NASDAQ listing.

Key metrics behind Nuvalent, Inc.'s NASDAQ-traded stock include a P/E ratio of -20.46 and a market capitalization of 9.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of NUVL on the NASDAQ.

Price Performance (NASDAQ: NUVL)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
18.72%
6-Month Change
22.95%
Year-to-Date (YTD) Change
23.23%
1-Year Change
61.41%
3-Year Change
188.88%
5-Year Change
409.29%
All-Time (Max) Change
561.12%

Contact Information

857 357 7000
One Broadway, Cambridge, MA, 02142

Company Facts

2,340 Employees
IPO DateJul 29, 2021
CountryUS

Frequently Asked Questions